Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab

Yıl: 2021 Cilt: 30 Sayı: 1 Sayfa Aralığı: 39 - 46 Metin Dili: İngilizce İndeks Tarihi: 17-05-2022

Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab

Öz:
Purpose: To evaluated the effi cacy of switching to intravitreal afl ibercept (IVA) injection to treat polypoidal choroidal vasculopathy (PCV) refractory to intravitreal ranibizumab (IVR). Materials and Methods: In this retrospective study, medical records of 29 eyes of 29 patients with PCV treated with IVA (2 mg / 0.05 mL) followed by IVR switch were reviewed. A treatment history of 3 consecutive monthly IVR as loading dose followed by a pro re nata regimen phase over 6 months was seen for all patients and followed by the last for 3 consecutive monthly of IVR received. All patients who were refractory to IVR (defi ned as recalcitrant subretinal or intraretinal fl uid in optical coherence tomography (OCT) and unchanged or decreased visual acuity (VA) compared with those at time of fi rst IVR injection, despite receiving the last 3 consecutive monthly IVR injections following 12 months. The switch time to IVA was accepted as the baseline. Visual and anatomical changes were recorded at baseline and at months 1, 3 and 6, respectively. Results: Visual acuity levels signifi cantly improved from 0.73 ± 0.49 logarithm of the minimum angle of resolution (log MAR) at baseline to 0.58 ± 0.38 log MAR 6 months after switching to afl ibercept (p = 0.037). The central macular thickness decreased signifi cantly from 349.58 ± 101.81 at baseline to 308.68 ± 94.58 at month 6 (p= 0.001). Of 16 eyes with polypoidal lesions at baseline, the polypoidal lesions regressed completely in 6 eyes (37%) at month 6. Conclusion: Administering intravitreal afl ibercept injection for patients with polypoidal choroidal vasculopathy refractory to ranibizumab maintained or improved visual acuity and reduced or eliminated exudative lesions and occluding polypoidal lesions without adverse events with short-term follow-up.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
  • 1. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1-8.
  • 2. Sho K , Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003;121:1392-6.
  • 3. RF Spaide , LA Yannuzzi, JS Slakter, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina. 1995;15:100-10.
  • 4. Song SJ, Youm DJ , Chang Y, et al. Age-related macular degeneration in a screened South Korean population: prevalence, risk factors, and subtypes. Ophthalmic Epidemiol 2009; 16:304- 10.
  • 5. Serbest K, Burçin A, Özdek Ş. Current Approaches to Diagnosis and Treatment of Polypoidal Choroidal Vasculopathy. Journal of Retina-Vitreus 2017;26;2.
  • 6. Şentürk F, Karaçorlu SA, Özdemir H, et al. Intravitreal Bevacizumab Therapy in Patients with Polypoidal Choroidal Vasculopathy. Journal of Retina-Vitreus 2009;17;3.
  • 7. Koh A , Lee WK, Chen LJ, et al. EVEREST study: effi cacy and safety of verteporfi n photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012;32:1453-64.
  • 8. Cho H J, Kim JW, Lee DW, et al. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Eye (Lond) 2012;26:426-33.
  • 9. Hikic hi T, Higuchi M, Matsushita T, et al. Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol 2013;97:617-21.
  • 10. Koh AH, Expert PCV Panel, Chen LJ, et al. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment.Retina 2013;33:686 716.
  • 11. Tan CS, Lim TH, Hariprasad SM. Current management of polypoidal choroidal vasculopathy. Ophthalmic Surg Lasers Imaging Retina 2015;46:786-91.
  • 12. Uy ama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol. 2002;133:639- 48.
  • 13. Hik ichi T, Ohtsuka H, Higuchi M, et al. Improvement of angiographic fi ndings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol. 2010;150:674-82.
  • 14. Koiz umi H , Kano M, Yamamoto A, et al.Afl ibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. Br J Ophthalmol 2015;99:1284-8.
  • 15. Tan C S , Ngo WK, Chen JP, et al. EVEREST Study Group; EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99:624-8.
  • 16. Rosenf eld PJ, Brown DM, Heier JS, et al. MARINA Study Group; Ranibizumab for neovascular age-related macular degeneration. New Engl J Med. 2006;355:1419-31.
  • 17. Comp arison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two year results. Ophthalmology 2012;119:1388-98.
  • 18. Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 Study Groups; Intravitreal afl ibercept (VEGF trap-eye) in wet agerelated macular degeneration. Ophthalmology. 2012;119:2537- 48.
  • 19. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 2008;92: 667-8.
  • 20. Bakall B , Folk JC, Boldt HC, et al. Afl ibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013;156:15- 22.
  • 21. Yamamoto A , Ok ada AA, Kano M, et al. One year results of intravitreal afl ibercept for polypoidal choroidal vasculopathy. Ophthalmology 2015;122:1866-72.
  • 22. Browning DJ, Kaiser PK, Rosenfeld PJ, et al. Afl ibercept for agerelated macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012;154:222-6.
  • 23. Lalwani GA , Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
  • 24.Saito M, Ka no M, Itagaki K, et al. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal afl ibercept injection. Jpn J Ophthalmol. 2016 Jan;60:35-41.
  • 25. Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010;29: 144-68.
  • 26. Tan CS, Ou yang Y, Ruiz H, et al. Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53:261-6.
  • 27. Usui S, Ikuno Y, Akiba M, et al. Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Invest Ophthalmol Vis Sci. 2012;53:2300-7.
  • 28. Kim JH, Lee TG, Chang YS, et al. Short-term choroidal thickness changes in patients treated with either ranibizumab or afl ibercept: a comparative study. Br J Ophthalmol 2016;100:1634-9.
  • 29. Cho HJ, Kim KM, Kim HS, et al. Intravitreal Afl ibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol. 2016;165:1-6.
  • 30. Lee WK, Iida T, Ogura Y, et al. PLANET Investigators. Effi cacy and Safety of Intravitreal Afl ibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol. 2018;136:786-93.
APA Karasu B, SÖNMEZ O (2021). Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. , 39 - 46.
Chicago Karasu Bugra,SÖNMEZ Orçun Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. (2021): 39 - 46.
MLA Karasu Bugra,SÖNMEZ Orçun Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. , 2021, ss.39 - 46.
AMA Karasu B,SÖNMEZ O Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. . 2021; 39 - 46.
Vancouver Karasu B,SÖNMEZ O Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. . 2021; 39 - 46.
IEEE Karasu B,SÖNMEZ O "Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab." , ss.39 - 46, 2021.
ISNAD Karasu, Bugra - SÖNMEZ, Orçun. "Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab". (2021), 39-46.
APA Karasu B, SÖNMEZ O (2021). Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. Retina-Vitreus, 30(1), 39 - 46.
Chicago Karasu Bugra,SÖNMEZ Orçun Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. Retina-Vitreus 30, no.1 (2021): 39 - 46.
MLA Karasu Bugra,SÖNMEZ Orçun Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. Retina-Vitreus, vol.30, no.1, 2021, ss.39 - 46.
AMA Karasu B,SÖNMEZ O Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. Retina-Vitreus. 2021; 30(1): 39 - 46.
Vancouver Karasu B,SÖNMEZ O Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab. Retina-Vitreus. 2021; 30(1): 39 - 46.
IEEE Karasu B,SÖNMEZ O "Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab." Retina-Vitreus, 30, ss.39 - 46, 2021.
ISNAD Karasu, Bugra - SÖNMEZ, Orçun. "Anatomical and Functional Outcomes Switching to Afl ibercebt Injection for Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab". Retina-Vitreus 30/1 (2021), 39-46.